Evidence map›Paper›PMID 40713496›Full record

ArticleBMC nephrology2025

Association of soluble urokinase plasminogen activator receptor and epidermal growth factor with histopathological findings of kidney biopsy: a single-center study.

Eman Nagy, Ahmed Almenshawy, Mostafa Abdelsalam, Ahmed M Abd Elwahab, Ola M Gharbia, Fatma El-Husseiny Moustafa, Nagy Sayed Ahmed, Nora A Khreba

Abstract read
In one paragraph

Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eman NagyMansoura Nephrology and Dialysis Unit (MNDU), Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. emannagy@mans.edu.eg.
Ahmed AlmenshawyClinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mostafa AbdelsalamMansoura Nephrology and Dialysis Unit (MNDU), Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed M Abd ElwahabMansoura Nephrology and Dialysis Unit (MNDU), Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ola M GharbiaRheumatology and Rehabilitation Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Fatma El-Husseiny MoustafaPathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Nagy Sayed AhmedMansoura Nephrology and Dialysis Unit (MNDU), Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Nora A KhrebaMansoura Nephrology and Dialysis Unit (MNDU), Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the crucial role of kidney biopsy in the management of various kidney diseases, it has inherent limitations. Therefore, the search for non-invasive biomarkers as alternative diagnostic and prognostic tools is warranted. The aim of this study was to assess the association between soluble urokinase plasminogen activator receptor (suPAR) and epidermal growth factor (EGF) levels and various histopathological findings in patients undergoing kidney biopsy.

methodsThis cross-sectional study involved patients who underwent kidney biopsies over a period of nine months. On the day of the biopsy, sociodemographic, clinical, and routine laboratory data were collected from patients' medical records. Urine samples were obtained for measurement of urinary suPAR, EGF, and creatinine levels. Kidney biopsies were reviewed and interpreted by an expert nephropathologist.

resultsA total of 82 patients (36 males) with a mean age of 36 years were included. The most common histopathological diagnosis was lupus nephritis (30.5%), followed by end-stage kidney disease (12%). Glomerulosclerosis (GS), tubular atrophy (TA), and interstitial fibrosis (IF) were present in 66%, 62%, and 74% of patients, respectively. Additionally, tubular injury, detached podocytes, and vascular fibrointimal thickening were observed in 30%, 5%, and 22% of patients, respectively. Both suPAR and EGF levels showed no statistically significant differences among varying degrees of GS, TA, and IF. However, urinary suPAR/creatinine was significantly higher in patients with tubular injury than in those without (p = 0.003). Its cut-off value to predict tubular injury was 0.08 with moderate sensitivity and specificity. Urinary EGF/creatinine was significantly lower in patients with detached podocytes than in those without (p = 0.028), whereas it was significantly higher in patients with vascular fibrointimal thickening than in those without (p = 0.043). Its cut-off value to predict vascular fibrointimal thickening was 0.88 with low-to-moderate sensitivity and moderate specificity.

conclusionsBoth urinary suPAR/creatinine and urinary EGF/creatinine ratios were not associated with either glomerulosclerosis or IF/TA, and therefore, cannot substitute for kidney biopsy in the assessment of kidney fibrosis. Higher urinary suPAR was associated with tubular injury, suggesting its potential link with acute tubular damage. In contrast, lower urinary EGF levels were found to be associated with podocyte detachment. Additionally, increased urinary EGF was associated with vascular fibrointimal thickening, suggesting a possible role in vascular remodeling. These findings highlight associations that warrant further investigation in longitudinal studies.

Indexed as

Epidermal Growth FactorKidneyKidney DiseasesReceptors, Urokinase Plasminogen ActivatorAdultBiomarkersBiopsyCross-Sectional StudiesFemaleHumansMaleMiddle AgedYoung AdultBiomarkersEpidermal Growth FactorReceptors, Urokinase Plasminogen ActivatorBiopsyEGFEpidermal growth factorFibrosisHistopathologyKidneySoluble urokinase plasminogen activator receptorSuPAR

Identifiers

PMID40713496
PMCPMC12291339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.